Overview

Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo as Monotherapy in Subjects With Advanced Melanoma of the Skin

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2027-03-01

Target enrollment:

Participant gender:

Summary

The aim of the study BCD-263-2/UNIVERSE is to demonstrate comparable efficacy and similar safety and immunogenicity profile of BCD-263 and Opdivo after repeated intravenous doses in subjects with advanced unresectable or metastatic melanoma of the skin.

Phase:

PHASE3

Details

Lead Sponsor:

Biocad

Treatments:

Nivolumab